Growth financing will help expand the Syn-One Test as investors place bigger bets on precision neurology and the future of earlier diagnosis.
One of the biggest frustrations in neurology is that by the time diseases such as Parkinson’s become obvious, they have often been quietly progressing for years. The tremors, stiffness and movement problems people associate with Parkinson’s are frequently the end result of damage that has already taken hold, leaving clinicians with fewer opportunities to intervene early.
That is why investors are increasingly turning their attention to diagnostics, not simply new drugs. Recently, CND Life Sciences announced growth financing led by S-Curve Partners, alongside participation from existing investors, to accelerate the expansion of its Syn-One Test platform and its broader precision neurology strategy [1].
The financing reflects a growing belief that the next leap in brain health may come not from treating disease after it appears, but from finding it while there is still time to act. For longevity medicine, extending healthspan increasingly depends on recognizing disease earlier, before symptoms become the whole story.
At first glance, the idea sounds almost counterintuitive. If Parkinson’s is a disease of the brain, why examine the skin? The answer lies in the body’s vast network of nerves. Much like branches extending from the trunk of a tree, nerves running through the skin remain connected to the broader nervous system. Researchers have found that the same abnormal protein linked to Parkinson’s and several related neurological disorders can also accumulate within these peripheral nerves.
Rather than trying to peer directly into the brain, the Syn-One Test looks for those biological fingerprints in a small skin biopsy. Think of it as spotting smoke before finding the fire itself. The skin may offer an accessible place where evidence of disease can be detected without needing invasive brain procedures.
CND says the test has now supported the diagnostic evaluation of more than 60,000 patients since its commercial launch in 2020, with more than 4,000 neurologists and other clinicians across the United States incorporating it into clinical practice.
A different approach to biomarkers
Neurology has entered what many describe as the biomarker era. Blood tests have transformed conversations around Alzheimer’s disease, while spinal fluid analysis continues to provide valuable information for clinicians. Parkinson’s, however, has proved more complicated.
Unlike a blood sample, which captures molecules circulating throughout the body, a skin biopsy allows clinicians to examine the tissue where abnormal alpha-synuclein has physically accumulated. It is less like measuring traces left behind in a river and more like inspecting the ground where footprints have been made.
That does not make one approach universally better than another. Instead, it highlights why different neurodegenerative diseases may require different biological windows. The more ways clinicians can objectively understand what is happening inside the body, the less they must rely solely on symptoms that often overlap between conditions.
That shift toward objective evidence is one reason interest in precision neurology continues to accelerate.
Finding the window before symptoms arrive
Perhaps the most intriguing opportunity lies even earlier. REM sleep behavior disorder, in which people physically act out vivid dreams during sleep, has become recognized as one of the strongest warning signs that Parkinson’s disease or related disorders may eventually develop. In many individuals, it can appear years before the classic movement symptoms emerge.
While the Syn-One Test is intended to assist clinicians in evaluating patients with suspected synucleinopathies, including REM sleep behavior disorder, its broader implications are difficult to ignore. If clinicians can identify the biological signs of disease during these earlier stages, future therapies designed to protect nerve cells may have a greater chance of succeeding because they would begin before significant damage has accumulated.
Earlier diagnosis alone does not prevent disease, but it could create the critical window in which prevention eventually becomes possible.
The new financing will support more than commercial expansion. CND plans to evolve Syn-One into part of a broader multimodal biomarker platform, while strengthening strategic partnerships and product innovation. That reflects a wider direction across medicine. Increasingly, no single test is expected to provide every answer. Instead, clinicians are beginning to combine multiple layers of information – from tissue biomarkers and genetics to imaging and emerging AI-powered digital measurements – to build a more complete picture of an individual’s neurological health.
Like assembling pieces of a puzzle, each biomarker adds context that helps reduce uncertainty. The future of diagnosis may not depend on one breakthrough alone, but on several complementary signals working together.
A longevity story, not just a neurology story
“We are pleased to deepen our relationship with S-Curve Partners and grateful for the continued support of existing investors and shareholders,” said Rick Morello, CEO of CND Life Sciences. “S-Curve’s confidence in CND’s mission reflects the progress our team has made in expanding clinical adoption and advancing the science behind our scalable neurodiagnostics platform.”
Dr Todd Levine, Chief Medical Officer and Co-Founder of CND, expressed optimism about the neuroscience field’s shift toward multimodal biomarkers and earlier intervention, noting that the financing provides the flexibility to invest in innovation, broaden access to the Syn-One platform, and deepen relationships with research and pharmaceutical partners.
Expanding on the broader scope, Daniel Livschutz, Founding Partner of S-Curve Partners, emphasized that neurodegenerative conditions remain widely underdiagnosed and misdiagnosed. He added that as disease-modifying therapies emerge, objective biomarkers will become increasingly critical for clinicians, patients, researchers and drug developers alike.
